Despite prolonged therapy (18 months), children with advanced non-lymphoblastic, non-Hodgkin's lymphoma (NHL) treated on previous Children's Cancer Group (CCG) trials achieved less than a 60% 5-year event-free survival (EFS). In this study we piloted a shorter but more intensive protocol ('Orange') to determine the feasibility, safety, and efficacy of this alternative treatment approach. Thirty-nine children received a CHOPbased induction, etoposide/ifosfamide consolidation, DECAL (dexamethasone, etoposide, cisplatin, cytosine arabinoside (Ara-C) and L-asparaginase) intensification, and either one or two similar but less intense maintenance courses. Patients were stratified to standard-risk (5 months) vs high-risk (7 months) treatment. High risk was defined as either bone marrow disease, CNS disease, mediastinal mass у one-third thoracic diameter at T5 and/or LDH у2 times institutional upper limits of normal. All other patients were considered to be standard risk. Results were compared with the previous CCG NHL study (CCG-503). Sixteen and 23 patients were considered standard-vs high-risk, respectively. The 5-year EFS and overall survival (OS) were 77 ± 7% and 80 ± 7%, respectively. The 5-year EFS and OS were significantly better in the standard-vs high-risk subgroups (100% vs 61 ± 11%) (P Ͻ 0.003) and (100% vs 65 ± 11%) (P Ͻ 0.01), respectively. Lactate dehydrogenase (LDH) у2 × normal (NL) was associated with significantly poorer outcomes (LDH у2 × NL vs Ͻ2 × NL) (5-year EFS: 55 ± 12% vs 100%) (P Ͻ 0.0004). This CCG hybrid regimen, 'Orange', of short and more intensive therapy resulted in a significant improvement in outcomes compared with the previous CCG trial of more prolonged but less intense therapy. This regimen that deletes high-dose methotrexate, if confirmed in a larger trial, could be considered as an alternative treatment approach in children without high tumor burdens (LDH Ͻ2 × NL) and Murphy stage III disease. Leukemia (2002) 16, 594-600.
Introduction
The treatment for advanced childhood non-lymphoblastic, non-Hodgkin's lymphoma has changed dramatically over the past 20 years. Anderson et al 1 initially reported successful results with the use of a four-drug regimen (COMP: cyclophosphamide, vincristine, methotrexate, and prednisone) in a Children's Cancer Group (CCG) study . In this original report, they demonstrated that COMP was significantly better than a 10-drug combination (modified LSA 2 -L 2 ) (57% vs 28% 2-year event-free survival (EFS). With a longer follow-up, And- erson et al 2 demonstrated that COMP continued to be significantly better than LSA 2 -L 2 for undifferentiated lymphoma (Burkitt's and non-Burkitt's). In an attempt to improve on the results of the previous study (CCG-551), CCG initiated a randomized, group-wide study testing whether the addition of daunomycin to COMP was more effective than COMP alone in the treatment of disseminated non-lymphoblastic, nonHodgkin's lymphoma (CCG-503). This protocol utilized prolonged and less intense therapy over an 18-month period. However, Chilcote et al 3 
demonstrated that the addition of daunomycin to COMP (D-COMP) did not improve the 5-year EFS (56 ± 4% vs 56 ± 5%) (D-COMP vs COMP).
A subsequent series of CCG pilot studies led to the development of this pilot phase II study ('Orange' regimen). Finlay et al 4 treated 68 children with advanced non-lymphoblastic lymphoma with a three-cycle induction lasting 9 weeks (cyclophosphamide, adriamycin, vincristine, prednisone) (intensive CHOP), intensive consolidation and intrathecal triple chemotherapy, and five 9-week courses of maintenance therapy. The intensive CHOP induction utilized in that study resulted in a 97% complete response rate (CR). 4 Results of CCG-8605, a retrieval protocol designed for children with recurrent solid tumors and/or lymphomas, demonstrated that the combination of ifosfamide and etoposide was an active combination in the reinduction therapy of recurrent/refractory non-Hodgkin's lymphoma (NHL) (J Miser, CCG-8605 Final Report, November 1997). Children with recurrent large cell lymphoma treated on this retrieval regimen had 20% and 40% CR and PR rates, respectively. Children with recurrent small non-cleaved lymphoma had 11% and 55% CR and PR rates, respectively, with this retrieval regimen. More recently, an alternative combination of chemotherapy was piloted for recurrent childhood NHL (CCG-5912) (DECAL: dexamethesone, etoposide, cisplatin, cytosine arabinoside and Lasparaginase). This regimen resulted in CR + PR rates in children with recurrent large cell lymphoma of 44% and 16%, respectively, and in recurrent small non-cleaved lymphoma of 23% and 15%, respectively. 5 Based on the results of these three pilot studies, we devised a CCG hybrid regimen ('Orange') to incorporate an intensive CHOP-based induction (CCG-552), ifosfamide/etoposide (VP-16) consolidation (CCG-8605), and DECAL intensification (CCG-5912) for short but more intense therapy (5 months in standard-risk and 7 months in high-risk) in children with advanced non-lymphoblastic NHL. In particular, this protocol omitted high-dose methotrexate (HDMTX) because of potential added co-morbidity to the incidence and severity of tumor lysis syndrome, which often accompanies childhood non-lymphoblastic lymphoma at presentation. We report the long-term follow-up with respect to feasibility, safety, and long-term outcome of this pilot phase II group-wide CCG trial (CCG-5911).
Materials and methods

Patient selection
Patient entry for this pilot trial was open to all institutions of the CCG between December 1991 and December 1993. IRB approval for the protocol was obtained by all participating institutions prior to patient entry and informed consent was obtained from patients and/or parents according to local institutional procedures. All newly diagnosed and untreated patients aged 21 years or less with biopsy-proven advanced non-lymphoblastic NHL at diagnosis were eligible for the study.
The eligibility criteria for advanced disease were similar but not identical to stages III and IV Murphy classification 6 but had to include at least one of the following: nodal disease that had extended beyond two lymphatic adjacent regions; intrathoracic (mediastinum or pleura) disease; incompletely resected primary disease of the GI tract; blasts in a bone marrow aspirate or a bone marrow biopsy positive for lymphoma; or presence of lymphoma cells with at least five white blood cells (WBC)/mm 3 in the cerebrospinal fluid (CSF). Submission of representative diagnostic slides was required. These slides, when received, were reviewed to confirm the diagnosis of non-lymphoblastic NHL. Both the institutional and review pathologists were asked to classify tumors according to the International Working Formulation. 7 At the time of study entry, patients were identified as having either high-risk or standard-risk disease. High-risk involved any or all of the following characteristics: (1) bone marrow involvement; (2) CNS involvement defined as the presence of lymphoma cells on cytospin with at least five WBC/mm 3 in the CSF or the presence of cranial neuropathy; (3) mediastinal mass of at least one-third of the thoracic diameter at the level of T5 or thoracic node involvement by lymphoma; or (4) serum lactate dehydrogenase (LDH) at least twice the institutional upper limit of normal. All other patients were considered to be standard-risk. Patients classified as high-risk received more intense CNS therapy and one additional course of maintenance.
Treatment plan
Patients received CHOP-based induction therapy with cyclophosphamide plus mesna, vincristine, doxorubicin, methylprednisolone and prednisolone, and intrathecal therapy (Table  1) . Consolidation consisted of 5 days of ifosfamide, mesna support, etoposide, and intrathecal therapy. Patients with CNS-positive disease received cranial irradiation during consolidation to a dose of 1800 cGy. Intensification consisted of dexamethasone, cytosine arabinoside (Ara-C), etoposide, Lasparaginase, cisplatin, and intrathecal therapy. Maintenance therapy consisted of three maintenance courses in standardrisk patients: first course -cyclophosphamide, vincristine, methylprednisolone, doxorubicin, and prednisolone; second course -ifosfamide plus mesna support and etoposide; third course -dexamethasone, Ara-C/etoposide, L-asparaginase, and cisplatin with intrathecal therapy. Patients defined as being high-risk received the same three maintenance courses repeated again (six total). Table 1 Orange regimen (CCG hybrid) 
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Study design
The study was initially designed as a feasibility study. Patients were allocated within high-and standard-risk strata to receive 'Orange' therapy. The plan was to enroll approximately 35 patients on this treatment regimen and, if six or more deaths in remission were noted on this regimen, enrollment was to be stopped and the treatment designated unacceptable with respect to toxicity.
Cardiac evaluation
Serial cardiac evaluations were required before each anthracycline dose to detect any cardiotoxicity. Cardiac evaluations consisted of an electrocardiogram and either echocardiogram or radionuclide cardiac angiogram (RNCA) with evaluation of systolic left ventricular performance. Cardiac evaluations were requested at baseline and before day 0 of each of the maintenance courses and at 4 and 12 months after completion of therapy.
Methods of analysis Toxicity and feasibility analysis:
Each patient who entered a particular course of therapy was evaluated for any grade III or IV toxicity as described in the National Cancer Institute (NCI) common toxicity criteria. The time required to complete each of the courses was compared with the planned course length. The last course was omitted from the planned course length analysis because the time at which the end of therapy evaluation was to be made was left to the discretion of the treating physician.
Survival analysis:
All data reported by February 2000 were used in the analysis. EFS was taken to be the time from study entry to relapse, progressive disease, documentation of resistant disease after the first course, death without evidence of disease progression, second malignancy, or last contact. 8 Patients who experienced a relapse, progressive disease, had documentation of resistant disease after the first course, died without evidence of disease progression, or had a second malignancy were considered to have suffered an adverse event; otherwise, the patient was censored at last contact. Survival (S) was taken to be the time from study entry to death. A death, regardless of cause, was considered an event; otherwise, the patient was censored at last contact.
Estimates of survival 9 were obtained by the method of Kaplan and Meier. Significance levels for comparisons were calculated using the log-rank statistic. Relative risks for adverse events and associated 95% confidence intervals were calculated from the proportional hazards regression model.
Results
Patient demographics
Forty-two (42) patients were entered on study to receive 'Orange' therapy. Of these, three were ineligible: one patient had lymphoblastic lymphoma, one patient had acute lymphocytic leukemia, and one patient received therapy prior to local IRB approval of the treatment protocol. The remaining 39 patients were included in the outcome analysis. Sixteen patients were considered to be standard-risk and 23 patients were considered high-risk. There were 27 males and 12 females (2.2:1.0) and the median age was 8 years (range 2-20 years). Murphy staging classification included one each stages I and II, 32 stage III patients, and five patients with stage IV disease. 6 There were 12 patients with large cell lymphoma and 27 with small non-cleaved lymphoma; 67% of patients had LDH у2 times upper normal institutional values, five patients had bone marrow involvement, and two patients had CNS disease (Table 2) . 
Event-free and overall survival
There have been 10 patient events in the 39 assessable patients. There have been three toxic deaths, two sepsis and one CNS toxicity, five relapses (four have died) and two secondary leukemias (one death). The 5-year EFS and overall survival were estimated to be 77 ± 7% and 80 ± 7%, respectively (Figure 1a and b) . For the standard-risk vs high-risk subgroups, the 5-year EFS and overall survival were 100% vs 61 ± 11% (P Ͻ 0.003) ( Figure 2 ) and 100% vs 65 ± 11% (P Ͻ 0.01), respectively.
Prognostic variables
The following variables were analyzed in a univariate analysis (age, sex, Murphy stage, LDH level, histology, bone marrow or CNS involvement) and demonstrated that LDH у2 × upper normal institutional values was a poor prognostic factor (5-year EFS: 55 ± 12% vs 100%) (P Ͻ 0.0004) (Figure 3 ) (5-year OS: 60 ± 11% vs 100%) (P Ͻ 0.002).
The 5-year OS was not significantly different by staging utilizing St Jude's staging classification (stage III vs IV) (5-year OS: stage III vs IV -82 ± 7% vs 60 ± 7%, respectively). 6 Although the number of patients was small, there was no difference between patients with bone marrow involvement (M1 (у5% blasts) and M2 (6-24% blasts) vs M3 (у25% blasts)) or CNS positive vs negative (5-year OS: M1 and M2 vs M3) (83 ± 7% vs 50 ± 35%, respectively) (CNS+ vs CNS-) (50 ± 35% vs 81 ± 7%, respectively).
Pathology
All histopathological material was classified by the institutional pathologist according to the International Working Formulation. Twelve of the 39 cases reviewed by the institutional pathologists were classified as large cell lymphomas (three anaplastic). Twenty-two of the 39 cases were classified as small non-cleaved cell lymphoma and five otherwise not specified. Large cell lymphomas had outcomes similar to other histological types (5-year EFS, large cell lymphomas vs other -92 ± 8% vs 70 ± 9%, respectively) and 5-year OS 92 ± 8 vs 74 ± 9%, respectively). The risk for adverse events with Event-free survival (a) and overall survival (b) by the method of Kaplan and Meier (n = 36).
Figure 2
Event-free survival comparing standard-risk vs high-risk stratification by the method of Kaplan and Meier (P Ͻ 0.003).
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Figure 3
Event-free survival by serum lactate dehydrogenase at study entry: two or more times institutional normal vs less than two times institutional normal (P Ͻ 0.0004).
Burkitt's type is similar to that for patients with other small non-cleaved histological subtypes (non-Burkitt's). Central immunophenotyping and central cytogenetics were not mandated on this study.
Toxicity
Three patients died in remission while being treated with the 'Orange' regimen. Despite administration of G-CSF, two children died of sepsis within 2 months of starting induction therapy. One patient with prior CNS disease died of CNS toxicity (spinal cord necrosis) during administration of intrathecal (IT) therapy. Following modification of IT therapy in March 1992, no further serious toxicities attributable to IT therapy occurred. The Orange regimen was amended to change the intrathecal therapy to high-risk patients. Triple IT therapy was amended in induction to patients with high risk and no CNS disease from days 0 and 2 to only Ara-C and hydrocortisone on days 0 and 14. In patients with CNS disease, triple IT therapy was decreased from days 0, 1, 2, 7, 10, 14 and 18 to days 0, 3, 7, 10 and 14. During consolidation, patients with high-risk disease but who were CNS negative had their triple IT therapy decreased from days 0, 7 and 14 to only IT Ara-C and hydrocortisone on days 0 and 14. Patients with high-risk disease and CNS positive had their triple IT therapy decreased from days 0, 3, 7, 10, 14 to days 0, 7 and 14.
The percents of grades III or IV toxicities that were у10% are noted by treatment course in Table 3 . Specifically, the incidences of grades III and IV renal toxicity during the induction phase were 2.6% and 0%, respectively. There was no incidence of grade III/IV renal toxicity or ototoxicity during the intensification regimen involving cisplatin in DECAL intensification. The average length and range of days during induction, consolidation, and intensification therapy were 24 (17-33), 23 (18-40), and 24 (20-38), respectively.
Follow-up cardiac evaluations revealed minimal abnormalities. Thirty-four patients had sequential follow-up studies. One patient (3%) had an abnormal fractional shortening (FS) on Echo (24%), and three patients had decreases of FS of less than 10 percentile points but remained in the normal range. The one patient with an abnormal FS on follow-up unfortu- nately had no baseline echocardiogram to determine whether this abnormality was treatment related. Two patients experienced secondary malignancies after enrollment on this study. Both were secondary leukemias classified as acute myelogenous leukemia and occurred only in the high-risk group of patients. One patient died and one was still alive at this reporting. Cytogenetics were unfortunately not available.
Discussion
In this pilot phase II trial of children with advanced non-lymphoblastic lymphoma, patients were stratified into two risk groups: high risk (у2 times normal institutional LDH values, bone marrow and/or CNS involvement) and standard risk (advanced disease but without elevated LDH, bone marrow or CNS involvement). This risk stratification is similar to the BFM-NHL 90 study recently reported by Reiter et al. 10 In the BFM stratification, patients with advanced childhood B-NHL were stratified into either R-2 (no or incomplete resection, extra-abdominal lymphoma) or abdominal lymphoma and LDH Ͻ500 U/l. The R-2 group classification was similar to our standard-risk classification. The BFM R-3 group was defined as no or incomplete resection, abdominal lymphoma and LDH у500 U/l, and/or bone marrow, CNS or multifocal bone involvement. This R-3 group was similar in many respects to our high-risk group. One of the major differences in therapy, however, was the omission of high-dose methotrexate (HDMTX) in the current CCG hybrid 'Orange' regimen compared to the use of 5 g/m 2 of HDMTX in R-2 and R-3 subgroups of BFM-NHL 90. However, the current 'Orange' regimen that does not utilize methotrexate utilizes 18 g/m 2 of ifosfamide and 1.6 g/m 2 of etoposide in patients with standard-risk disease, and these doses of ifosfamide and VP-16 are currently higher than other pediatric regimens that utilize high-dose methotrexate for childhood non-lymphoblastic lymphoma. 10, 11 In comparing the standard-risk CCG group and the R-2 BFM group, the 5-year EFS was similar (100% vs 96 ± 2%, respectively). Therefore, in this subgroup of children with non-lymphoblastic B non-Hodgkin's lymphoma, Murphy stage III (incompletely resected) but low tumor burden (low or normal LDH), the outcome is both similar and superb (у95% 5-year EFS) utilizing either approach of the two cooperative groups. 10 However, in the current CCG regimen, the use of high-dose methotrexate was omitted. In contrast, in the higher risk group in our current study and the R-3 risk group in the BFM-NHL 90 study, the 4-year EFS was only 55 ± 14% in the current study compared to a 6-year EFS of 78 ± 3% in the BFM-NHL 90 study. 10 This comparison suggests the critical importance of HDMTX in children with higher tumor burdens (LDH у500 IU/l or у2 times NL) and/or more disseminated disease. 10 This finding is further illustrated by the differences in outcome of children with abdominal Murphy stage III B-NHL and LDH у500 IU/l between the BFM-NHL 86 and BFM-NHL 90 studies. In the BFM-NHL 86 study, the dose of methotrexate was only 500 mg/m 2 compared to 5000 mg/m 2 in the BFM-NHL 90 study. The increase in the HDMTX in this subgroup of patients in the BFM-NHL 90 study resulted in the 6-year EFS significantly improved from 29 ± 14% to 81 ± 4% (P Ͻ 0.0001), respectively. 10, 11 Therefore, it appears that, in children with advanced non-lymphoblastic B-NHL and a high tumor burden, the use of HDMTX is critically important to enhance overall outcome.
In other comparisons, the Pediatric Oncology Group (POG) demonstrated that utilizing 'Total-B' therapy (fractionated cyclophosphamide and four courses of HDMTX (1 g/m 2 /course)) in children with stage III high-grade small non-cleaved lymphomas, the 3-year EFS was 79 ± 6%.
12 To achieve these results, however, four doses of HDMTX (1 ) in group C patients with either bone marrow and/or CNS involvement and achieved a greater than 80% 3-year EFS. These French results improved significantly for this subset of patients from the previous LMB-84 study, which utilized only 3 g/m 2 of HDMTX in patients with B-ALL and/or Murphy stage IV disease and resulted in only a 3-year EFS of 68 ± 8%. 15 The incidence of grade III and IV renal toxicity during the induction phase of this protocol was 2.6% and 0%, respectively. This compares with an incidence of 21% of acute renal failure in children with advanced Burkitt's lymphoma or B-ALL treated on Total-B therapy. 13 In the current pediatric international B cell lymphoma study (FAB/LMB-95) (CCG-5961), the incidence of acute renal failure requiring dialysis in patients with advanced Burkitt's lymphoma or B-ALL is currently at 18% (M Cairo, personal communication).
Two patients (5%) in the high-risk subgroup treated on this protocol developed secondary acute myelogenous leukemia. They each received 2.3 g/m 2 of etoposide (VP-16). Total-B therapy in the POG studies did not utilize VP-16 and the BFM-NHL 90 study utilized only a total of 600 mg/m 2 (200 mg/m 2 /course × 3 courses) in their R-2 and R-3 subgroup of patients. These doses of VP-16 are substantially less than those used in our current study. These results suggest the need to utilize VP-16 at lower doses similar to doses used in BFM-NHL 90 10 or possibly to delete VP-16 in future studies. Furthermore, the role and importance of cisplatin in the intensi-fication 'DECAL' arm in this current regimen is also unclear. Little is known about the efficacy of cisplatin as a single agent in children with non-lymphoblastic NHL and it is not used in other successful childhood non-lymphoblastic lymphoma regimens.
Unfortunately, this pilot phase II trial did not mandate performance of central immunophenotyping and/or cytogenetics. Only three patients had anaplastic large cell histology and therefore there were too few patients to analyze the effects of this regimen in this histological subtype. However, in this study and in the previous CCG study (503) in children with advanced non-lymphoblastic NHL, histological subtype comparisons between large cell and small non-cleaved cell lymphomas demonstrated a trend for better outcome for large cell lymphoma, although not statiscally different.
In summary, this pilot phase II trial of short but more intensive multiagent chemotherapy, without high-dose methotrexate, was well tolerated in children with advanced non-lymphoblastic NHL. In a small subgroup with advanced disease (Murphy stage III but without a high tumor burden) (LDH Ͻ2 × NL) and without disseminated disease (bone marrow and/or central nervous system disease) (BM/CNS), the 5-year EFS was 100%. These results in this small subgroup should be confirmed in a larger series. If confirmed in a larger series, this subgroup of patients with advanced disease but low tumor burden may benefit from this alternative treatment approach. However, in children with more disseminated disease (BM/CNS) and/or high tumor burden (LDH у2 × NL), this approach that omits high-dose methotrexate is inferior to other pediatric NHL cooperative group results and therefore should be abandoned. The minimum dose, if any, of VP-16 required in this regimen needs to be explored in future investigations. Based on the results of this study, the current CCG-5961 study is exploring the appropriate doses of Ara-C and VP-16 in childhood B-NHL.
